Weichang'an and 5-fluorouracil suppresses colorectal cancer in a mouse model

被引:0
|
作者
Li Tao [1 ]
Jin-Kun Yang [1 ]
Ying Gu [1 ]
Xin Zhou [2 ]
Ai-Guang Zhao [1 ]
Jian Zheng [1 ]
Ying-Jie Zhu [1 ]
机构
[1] Department of Oncology,Longhua Hospital Shanghai University of Traditional Chinese Medicine
[2] Department of Pharmacy,Longhua Hospital,Shanghai University of Traditional Chinese Medicine
关键词
Colorectal cancer; Hepatic metastasis; Weichang’an formula; Orthotopic transplant nude mouse model; Chemotherapeutics; 5-fluorouracil;
D O I
暂无
中图分类号
R735.35 [];
学科分类号
100214 ;
摘要
AIM: To examine the effect of Weichang’an(WCA) and 5-fluorouracil(5-Fu) on colorectal tumor and hepatic metastasis in a mouse model. METHODS: Quantitative determination of hesperidin, the effective component in WCA decoction, was performed using Hp LC. In vitro cytotoxicity of WCA was determined by treating HCT-116 cells with WCA diluents or serum extracted from rats that received WCA by oral gavage for 1 wk and MTT assays. Forty-eight nude mice received cecum implantation with tumor blocks subcutaneously amplified from human colon cancer cell line HCT-116. Mice were randomly divided into four treatment groups: control(CON), WCA, 5-Fu and combination(WCA + 5-Fu). pathological examination of tumors consisted of tissue sectioning and hematoxylin and eosin staining. Tumor weight and size were measured, and the number of metastatic l e s i o n s wa s c o u n t e d. S e r u m c a r c i n o e m b r yo n i c antigen(CEA) level was determined by ELISA. The expression levels of tumor genesis and metastasisrelated proteins β-catenin and matrix metalloproteinase(MMp)-7 were measured by real-time quantitative reverse transcriptase polymerase chain reaction(RTp CR), immunohistochemistry and immunoblotting. Cell fractionation was used to investigate intracellular distribution of β-catenin.RESULTS: parenchymal tumors were palpable in the abdomens of nude mice 2 wk post-implantation and orthotopic tumor formation rate was 100% in all groups. 5-Fu treatment alone significantly decreased tumor weight compared to the CON group(1.203 ± 0.284 g vs 1.804 ± 0.649 g, p < 0.01). WCA treatment alone reduced the rate of metastasis(50% vs 100%,p < 0.05). Combination treatment of WCA + 5-Fu was the most effective, reducing the tumor weight(1.140 ± 0.464 g vs 1.804 ± 0.649 g, p < 0.01) and size(1493.438 ± 740.906 mm3 vs 2180.259 ± 816.556 mm3, p < 0.05), the rate of metastases(40% vs 100%, p < 0.01), and serum CEA levels(31.263 ± 7.421 μg/L vs 43.040 ± 11.273 μg/L, p < 0.05). Expression of β-catenin and MMp-7 was decreased in drug-treated groups compared to controls, as detected using realtime quantitative RT-p CR, immunohistochemistry and immunoblotting, respectively. Cell fractionation assays revealed that nuclear translocation of β-catenin was reduced by WCA and/or 5-Fu treatments. CONCLUSION: Combination of WCA with 5-Fu significantly inhibited colon tumor growth and hepatic metastases. Decreased expression of β-catenin and MMp-7 may be important.
引用
收藏
页码:1125 / 1139
页数:15
相关论文
共 50 条
  • [21] CISPLATIN + 5-FLUOROURACIL VERSUS 5-FLUOROURACIL ALONE IN ADVANCED COLORECTAL-CANCER - A RANDOMIZED STUDY
    LABIANCA, R
    PANCERA, G
    CESANA, B
    CLERICI, M
    MONTINARI, F
    LUPORINI, G
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (10): : 1579 - 1581
  • [22] Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer
    I Chau
    A Webb
    D Cunningham
    M Hill
    J S Waters
    A Norman
    A Massey
    [J]. British Journal of Cancer, 2001, 85 : 1258 - 1264
  • [23] Biochemical modulation of 5-fluorouracil with methotrexate in advanced colorectal cancer patients pretreated with adjuvant 5-fluorouracil and leucovorin
    Pronzato, P
    Vaira, F
    Vigani, A
    Losardo, P
    Bertelli, G
    [J]. ANTICANCER RESEARCH, 1995, 15 (6B) : 2679 - 2682
  • [24] Suppression of tumour growth by rapamycin and 5-fluorouracil in a syngenic mouse model for colorectal peritoneal carcinosis
    Wagner, M
    Trochsler, M
    Candinas, D
    Stroka, D
    Anouyi, E
    Vorburger, SA
    [J]. BRITISH JOURNAL OF SURGERY, 2005, 92 (07) : 910 - 910
  • [25] Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer
    Chau, I
    Webb, A
    Cunningham, D
    Hill, M
    Waters, JS
    Norman, A
    Massey, A
    [J]. BRITISH JOURNAL OF CANCER, 2001, 85 (09) : 1258 - 1264
  • [26] CHEMOTHERAPY FOR COLORECTAL CANCER WITH 5-FLUOROURACIL, CYCLOPHOSPHAMIDE, AND CCNU - COMPARISON OF ORAL AND CONTINUOUS IV ADMINISTRATION OF 5-FLUOROURACIL
    BEDIKIAN, AY
    STAAB, R
    LIVINGSTON, R
    VALDIVIESO, M
    BURGESS, MA
    BODEY, GP
    [J]. CANCER TREATMENT REPORTS, 1978, 62 (10): : 1603 - 1605
  • [27] COMPARISON OF 5-FLUOROURACIL WITH 5-FLUOROURACIL, CYCLOPHOSPHAMIDE, AND METHOTREXATE IN METASTATIC COLORECTAL CARCINOMA
    RICHARDS, F
    PAJAK, TL
    COOPER, MR
    SPURR, CL
    [J]. CANCER, 1975, 36 (05) : 1589 - 1592
  • [28] Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer
    Di Paolo, A
    Danesi, R
    Vannozzi, F
    Falcone, A
    Mini, E
    Cionini, L
    Ibrahim, T
    Amadori, D
    Del Tacca, M
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (06) : 627 - 637
  • [29] Chronotherapy with 5-fluorouracil, oxaliplatin, and folinic acid in colorectal cancer
    Sandor, V
    [J]. LANCET, 1997, 350 (9087): : 1325 - 1326
  • [30] Oral status in patients receiving 5-fluorouracil for colorectal cancer
    Djuric, M.
    Cakic, S.
    Hadzi-Mihailovic, M.
    Petrovic, D.
    Jankovic, L.
    [J]. JOURNAL OF BUON, 2010, 15 (03): : 475 - 479